Cigna Group Affirms 2024 Financial Guidance

TL;DR

Cigna Group confirms 2024 EPS guidance of $25.40-$26.00.

AI Summary

On June 6, 2024, The Cigna Group filed an 8-K to affirm its previously issued financial guidance for the full year 2024. The company reiterated its expectation for Adjusted Earnings Per Share (EPS) to be in the range of $25.40 to $26.00. This affirmation comes as the company continues to operate under its existing business structure.

Why It Matters

This filing reassures investors that Cigna Group is on track to meet its previously stated financial targets for the year, providing stability in its outlook.

Risk Assessment

Risk Level: low — The filing is a routine affirmation of existing guidance, not a change in financial performance or outlook.

Key Numbers

• $25.40-$26.00 — Adjusted EPS Guidance (Full year 2024 expectation)

Key Players & Entities

• The Cigna Group (company) — Registrant
• 2024 (date) — Fiscal year for guidance
• $25.40 to $26.00 (dollar_amount) — Adjusted Earnings Per Share guidance

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc. I
• $28.40 — ations on a per share basis of at least $28.40 per share. Additionally, the Company re
• $3.2 billion — agreements to purchase an aggregate of $3.2 billion of the Company's common stock as part o
• $4.4 billion — This year, the Company has repurchased $4.4 billion of common stock through May 31, 2024. T
• $5.0 billion — Company remains on track to repurchase $5.0 billion of common stock in the first half of 20

Filing Documents

• cigna8k.htm (8-K) — 33KB
• 0000950159-24-000212.txt ( ) — 204KB
• ci-20240606.xsd (EX-101.SCH) — 3KB
• ci-20240606_lab.xml (EX-101.LAB) — 33KB
• ci-20240606_pre.xml (EX-101.PRE) — 22KB
• cigna8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. 2024 Outlook Affirmation The Cigna Group (the "Company" or "our") officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, The Cigna Group officials expect to reaffirm projected full year 2024 consolidated adjusted income from operations on a per share basis of at least $28.40 per share. Additionally, the Company recently completed the previously announced accelerated share repurchase agreements to purchase an aggregate of $3.2 billion of the Company's common stock as part of its existing share repurchase program. This year, the Company has repurchased $4.4 billion of common stock through May 31, 2024. The Company remains on track to repurchase $5.0 billion of common stock in the first half of 2024 and continues to expect the majority of discretionary cash flow to be used for share repurchase this year. The Cigna Group previously discussed its full year 2024 outlook in its press release and investor presentation dated May 2, 2024, and during the related investor conference call. The press release, presentation and the conference call transcript are available in the Investor Relations section of The Cigna Group's website located at www.thecignagroup.com. Forward-looking statements in these documents and the related call speak only as of the date they were made. Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group's management because it presents the underlying results of operations of the Company's businesses and permits analysis of trends in underlying revenue, expenses and shareholders' net income (loss). Adjusted income from operations is defined as shareholders' net income (loss) (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and

Forward-looking statements are subject to

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of potential cyberattack or other privacy or data security incidents; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operatio

View Full Filing

View this 8-K filing on SEC EDGAR